PHOTO
This is a new paradigm in cancer diagnosis and management in UAE.
Liquid Biopsy is a blood test that detects changes in normal DNA sequence shed by cancer cells in the blood. It can be used to predict cancer relapse well ahead of time even before tumors are seen on scans. This test could easily help clinicians and patient stay a step ahead of cancer by monitoring the changes and thus reactively picking treatments that fit attacking a particular tumor.
When conducted over a period of time, the blood test is capable of tracking the genetic changes or mutational changes that occur over a period of time and predict accurately if the cancer is about to return. The test is not only non invasive but also can be done repeatedly to capture the mutations accumulated over a period of time and accurately predicts metastatic relapse in patients which then allows for a better decision in treatment. It allows for a personalised treatment.
The Liquid Bioposy Lab is an outcome of Translational Cancer Research at the Gulf Medical University researchers led by Prof. Salem Chouaib, the well known internationally in the field of cancer immunology – leading the Thumbay Research Institute for Precision Medicine.
Prof. Salem indicated that this new achievement is due to the support for research provided by GMU and the Thumbay Hospitals. It is a reflection of the colloboration in UAE between researchers and hospitals who have contributed to this achievement. Sheikh Khalifa Hospital Ras Al Khaimah is one of our main colloborator in this domain.
We are ready to colloborate with all the cancer centers in UAE and the Gulf region in order to use our Liquid Bioposy Lab and to make it a Center of Excellence in Cancer Genomic and Immuno-oncology in UAE.
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
